文献

J-GLOBAL ID：201702248840715061   整理番号：17A0135920

チャールソン併存疾患指数はチロシンキナーゼ阻害剤で治療したCML患者の転帰不良を予測する

Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor

著者 (10件)： Uemura Makiko (Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-town, Japan) ,  Imataki Osamu (Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-town, Japan) ,  Imataki Osamu (Division of Hematology and Stem Cell Transplantation, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-town, Kagawa, Japan) ,  Kawachi Yasunori (Division of Hematology, Department of Internal Medicine, Kaisei General Hospital, The Taijukai Foundation, Sakaide City, Kagawa, Japan) ,  Kawachi Yasunori (Division of Hematology, Department of Internal Medicine, Takamatsu Red Cross Hospital, Takamatsu City, Kagawa, Japan) ,  Kawakami Kimihiro (Division of Hematology, Department of Internal Medicine, Kagawa Prefectural Central Hospital, Takamatsu City, Kagawa, Japan) ,  Hoshijima Yasuo (Department of Internal Medicine, Takamatsu Municipal Hospital, Takamatsu City, Kagawa, Japan) ,  Matsuoka Akihito (Department of Internal Medicine, Sakaide City Hospital, Sakaide City, Kagawa, Japan) ,  Matsuoka Akihito (Division of Hematology, Department of Internal Medicine, Mitoyo General Hospital, Kanonji City, Kagawa, Japan) ,  Kadowaki Norimitsu (Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-town, Japan)
資料名： International Journal of Hematology  (International Journal of Hematology)
巻： 104  号： 5  ページ： 621-627  発行年： 2016年11月 
JST資料番号： F0888A  ISSN： 0925-5710  CODEN： IJHEEY  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： ドイツ (DEU)  言語： 英語 (EN)

抄録/ポイント： SokalおよびHasfordスコアリングシステムは慢性骨髄...

シソーラス用語： *判定基準 ,...
準シソーラス用語： *チャールソン併存疾患指数 ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0135920&from=J-GLOBAL&jstjournalNo=F0888A") }}

著者キーワード (5件)： Chronic myeloid leukemia ,  Tyrosine kinase inhibitor ,  Charlson comorbidity index ,  Sokal score ,  Hasford score

分類 (2件)： 臨床腫よう学一般  (GE03010Y) ,  血液の腫よう  (GK04000M)

引用文献 (18件)：

• Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012;120:1390-7.
• Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-17.
• Höglund M, Sandin F, Hellström K, Björeman M, Björkholm M, Brune M, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122:1284-92.
• Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553-61.
• Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789-99.

タイトルに関連する用語 (6件)： チャールソン併存疾患指数 ,  チロシンキナーゼ阻害剤 ,  治療 ,  CML ,  患者の転帰 ,  予測